Glycoprotein nonmetastatic melanoma protein B ameliorates skeletal muscle lesions in a SOD1G93A mouse model of amyotrophic lateral sclerosis

Journal of Neuroscience Research

Volumn 93, Issue 10, 2015, Pages 1552-1566

  Nagahara, Yuki ^a   Shimazawa, Masamitsu ^a   Tanaka, Hirotaka ^a   Ono, Yoko ^a   Noda, Yasuhiro ^a   Ohuchi, Kazuki ^a   Tsuruma, Kazuhiro ^a   Katsuno, Masahisa ^b   Sobue, Gen ^b   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ALS; Amyotrophic lateral sclerosis; Glycoprotein nonmetastatic melanoma protein B; GPNMB; Neuromuscular junction; Skeletal muscle; Sporadic ALS; Transgenic mouse

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN NONMETASTATIC MELANOMA PROTEIN B; PLASMID DNA; UNCLASSIFIED DRUG; GPNMB PROTEIN, HUMAN; MEMBRANE PROTEIN; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE; SYNAPTOPHYSIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL COUNT; CONTROLLED STUDY; EXPRESSION VECTOR; GASTROCNEMIUS MUSCLE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; MOUSE; MSOD1 MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE DENERVATION; MUSCLE INJURY; MUSCLE MASS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; AGED; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; IMMUNOLOGY; METABOLISM; MUSCULAR ATROPHY; NEUROMUSCULAR JUNCTION; PATHOLOGY; TRANSGENIC MOUSE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEUROMUSCULAR JUNCTION; SUPEROXIDE DISMUTASE; SYNAPTOPHYSIN;

EID: 84939466101     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23619     Document Type: Article

References (62)

1. Abdelmagid SM, Barbe MF, Rico MC, Salihoglu S, Arango-Hisijara I, Selim AH, Anderson MG, Owen TA, Popoff SN, Safadi FF. 2008. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res 314:2334-2351.
2. Ahmadi M, Liu JX, Brannstrom T, Andersen PM, Stal P, Pedrosa-Domellof F. 2010. Human extraocular muscles in ALS. Invest Ophthalmol Vis Sci 51:3494-3501.
3. Audouard E, Schakman O, Rene F, Huettl RE, Huber AB, Loeffler JP, Gailly P, Clotman F. 2012. The Onecut transcription factor HNF-6 regulates in motor neurons the formation of the neuromuscular junctions. PloS One 7:e50509.
4. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. 1998. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123.
5. Bensimon G, Lacomblez L, Meininger V. 1994. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585-591.
6. Boyer JG, Ferrier A, Kothary R. 2013. More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases. Front Physiol 4:356.
7. Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K. 2007. Syndecan-4 mediates the coinhibitory function of DC-HIL on T-cell activation. J Immunol 179:5778-5784.
8. Chung JS, Bonkobara M, Tomihari M, Cruz PD Jr, Ariizumi K. 2009. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol 39:965-974.
9. Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes M, Lee SK, Vetto AP, Petrosyan S, Marsala M, Murphy AN, Williams DS, Spiegelman BM, Cleveland DW. 2012. Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab 15:778-786.
10. Dion PA, Daoud H, Rouleau GA. 2009. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev 10:769-782.
11. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD. 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185:232-240.
12. Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. 2000. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci 20:2534-2542.
13. Furochi H, Tamura S, Mameoka M, Yamada C, Ogawa T, Hirasaka K, Okumura Y, Imagawa T, Oguri S, Ishidoh K, Kishi K, Higashiyama S, Nikawa T. 2007a. Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fibroblasts. FEBS Lett 581:5743-5750.
14. Furochi H, Tamura S, Takeshima K, Hirasaka K, Nakao R, Kishi K, Nikawa T. 2007b. Overexpression of osteoactivin protects skeletal muscle from severe degeneration caused by long-term denervation in mice. J Med Invest 54:248-254.
15. Gifondorwa DJ, Robinson MB, Hayes CD, Taylor AR, Prevette DM, Oppenheim RW, Caress J, Milligan CE. 2007. Exogenous delivery of heat shock protein 70 increases lifespan in a mouse model of amyotrophic lateral sclerosis. J Neurosci 27:13173-13180.
16. Gifondorwa DJ, Jimenz-Moreno R, Hayes CD, Rouhani H, Robinson MB, Strupe JL, Caress J, Milligan C. 2012. Administration of recombinant heat shock protein 70 delays peripheral muscle denervation in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurol Res Int 2012:170426.
17. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. 1994. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264:1772-1775.
18. Henry TD, Hirsch AT, Goldman J, Wang YL, Lips DL, McMillan WD, Duval S, Biggs TA, Keo HH. 2011. Safety of a nonviral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther 18:788-794.
19. Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K, Hearing VJ. 2010. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J 24:1616-1629.
20. Hu X, Zhang P, Xu Z, Chen H, Xie X. 2013. GPNMB enhances bone regeneration by promoting angiogenesis and osteogenesis: potential role for tissue engineering bone. J Cell Biochem 114:2729-2737.
21. Huang C, Tong J, Bi F, Zhou H, Xia XG. 2012. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. J Clin Invest 122:107-118.
22. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, Razvi S, Symes JF. 1998. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 28:964-973; discussion 973-965.
23. Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, MacLea KS, Freibaum B, Li S, Molliex A, Kanagaraj AP, Carter R, Boylan KB, Wojtas AM, Rademakers R, Pinkus JL, Greenberg SA, Trojanowski JQ, Traynor BJ, Smith BN, Topp S, Gkazi AS, Miller J, Shaw CE, Kottlors M, Kirschner J, Pestronk A, Li YR, Ford AF, Gitler AD, Benatar M, King OD, Kimonis VE, Ross ED, Weihl CC, Shorter J, Taylor JP. 2013. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495:467-473.
24. Kim JM, Jeong JG, Ho SH, Hahn W, Park EJ, Kim S, Yu SS, Lee YW, Kim S. 2003. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 10:1543-1550.
25. Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. 2004. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med 10:530-534.
26. Kuan CT, Wakiya K, Dowell JM, Herndon JE 2nd, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. 2006. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12:1970-1982.
27. Leger B, Vergani L, Soraru G, Hespel P, Derave W, Gobelet C, D'Ascenzio C, Angelini C, Russell AP. 2006. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J 20:583-585.
28. Li W, Brakefield D, Pan Y, Hunter D, Myckatyn TM, Parsadanian A. 2007. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp Neurol 203:457-471.
29. Lu Q, Yao Y, Yao Y, Liu S, Huang Y, Lu S, Bai Y, Zhou B, Xu Y, Li L, Wang N, Wang L, Zhang J, Cheng X, Qin G, Ma W, Xu C, Tu X, Wang Q. 2012. Angiogenic factor AGGF1 promotes therapeutic angiogenesis in a mouse limb ischemia model. PloS One 7:e46998.
30. Matsuki A, Yamamoto S, Nakagami H, Aoki M, Tamai K, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R. 2004. No influence of tumor growth by intramuscular injection of hepatocyte growth factor plasmid DNA: safety evaluation of therapeutic angiogenesis gene therapy in mice. Biochem Biophys Res Commun 315:59-65.
31. Nikawa T, Ishidoh K, Hirasaka K, Ishihara I, Ikemoto M, Kano M, Kominami E, Nonaka I, Ogawa T, Adams GR, Baldwin KM, Yasui N, Kishi K, Takeda S. 2004. Skeletal muscle gene expression in space-flown rats. FASEB J 18:522-524.
32. Ogawa T, Nikawa T, Furochi H, Kosyoji M, Hirasaka K, Suzue N, Sairyo K, Nakano S, Yamaoka T, Itakura M, Kishi K, Yasui N. 2005. Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice. Am J Physiol 289:C697-C707.
33. Onaga M, Ido A, Hasuike S, Uto H, Moriuchi A, Nagata K, Hori T, Hayash K, Tsubouchi H. 2003. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet accelerates motility of hepatoma cells. J Hepatol 39:779-785.
34. Ono Y, Tanaka H, Takata M, Nagahara Y, Noda Y, Tsuruma K, Shimazawa M, Hozumi I, Hara H. 2014. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci Lett 559:174-178.
35. Osawa K, Okubo Y, Nakao K, Koyama N, Bessho K. 2010. Osteoinduction by repeat plasmid injection of human bone morphogenetic protein-2. J Gene Med 12:937-944.
36. Rastogi S, Guerrero M, Wang M, Ilsar I, Sabbah MS, Gupta RC, Sabbah HN. 2011. Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs. Am J Physiol Heart Circ Physiol 300:H1501-H1509.
37. Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan CT, Bigner DD, Counter CM, Wang XF. 2003. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278:15951-15957.
38. Ripoll VM, Meadows NA, Raggatt LJ, Chang MK, Pettit AR, Cassady AI, Hume DA. 2008. Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB. Gene 413:32-41.
39. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, Siegel PM. 2007. Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5:1001-1014.
40. Rose AA, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM. 2010. ADAM10 releases a soluble form of the GPNMB/osteoactivin extracellular domain with angiogenic properties. PloS One 5:e12093.
41. Sakowski SA, Lunn JS, Busta AS, Oh SS, Zamora-Berridi G, Palmer M, Rosenberg AA, Philip SG, Dowling JJ, Feldman EL. 2012. Neuromuscular effects of G93A-SOD1 expression in zebrafish. Mol Neurodegener 7:44.
42. Schgoer W, Theurl M, Jeschke J, Beer AG, Albrecht K, Gander R, Rong S, Vasiljevic D, Egger M, Wolf AM, Frauscher S, Koller B, Tancevski I, Patsch JR, Schratzberger P, Piza-Katzer H, Ritsch A, Bahlmann FH, Fischer-Colbrie R, Wolf D, Kirchmair R. 2009. Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism. Circ Res 105:994-1002.
43. Selim AA, Abdelmagid SM, Kanaan RA, Smock SL, Owen TA, Popoff SN, Safadi FF. 2003. Antiosteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit Rev Eukaryot Gene Expr 13:265-275.
44. Sheng MH, Wergedal JE, Mohan S, Lau KH. 2008. Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett 582:1451-1458.
45. Shigematsu H, Yasuda K, Sasajima T, Takano T, Miyata T, Ohta T, Tanemoto K, Obitsu Y, Iwai T, Ozaki S, Ogihara T, Morishita R. 2011. Transfection of human HGF plasmid DNA improves limb salvage in Buerger's disease patients with critical limb ischemia. Int Angiol 30:140-149.
46. Shimazawa M, Tanaka H, Ito Y, Morimoto N, Tsuruma K, Kadokura M, Tamura S, Inoue T, Yamada M, Takahashi H, Warita H, Aoki M, Hara H. 2010. An inducer of VGF protects cells against ER stress-induced cell death and prolongs survival in the mutant SOD1 animal models of familial ALS. PloS One 5:e15307.
47. Singh M, Del Carpio-Cano F, Belcher JY, Crawford K, Frara N, Owen TA, Popoff SN, Safadi FF. 2010. Functional roles of osteoactivin in normal and disease processes. Crit Rev Eukaryot Gene Expr 20:341-357.
48. Sunyach C, Michaud M, Arnoux T, Bernard-Marissal N, Aebischer J, Latyszenok V, Gouarne C, Raoul C, Pruss RM, Bordet T, Pettmann B. 2012. Olesoxime delays muscle denervation, astrogliosis, microglial activation, and motoneuron death in an ALS mouse model. Neuropharmacology 62:2346-2352.
49. Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H. 2013. Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental amyotrophic lateral sclerosis models. Br J Pharmacol 70:341-351.
50. Tanaka H, Shimazawa M, Kimura M, Takata M, Tsuruma K, Yamada M, Takahashi H, Hozumi I, Niwa J, Iguchi Y, Nikawa T, Sobue G, Inuzuka T, Hara H. 2012. The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci Rep 2:573.
51. Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. 2001. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 8:181-189.
52. Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, MacDougall JR, Rastelli L, Herrmann J, Gallo M, Gazit-Bornstein G, Senter PD, Meyer DL, Lichenstein HS, LaRochelle WJ. 2006. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373-1382.
53. Utsunomiya K, Owaki K, Okumura Y, Yano M, Oto T, Suzuki E, Tamura S, Abe T, Kohno S, Ohno A, Hirasaka K, Teshima-Kondoh S, Nikawa T. 2012. An intracellular fragment of osteoactivin formed by ectodomain shedding translocated to the nucleoplasm and bound to RNA binding proteins. Biosci Biotechnol Biochem 76:2225-2229.
54. Warita H, Abe K, Setoguchi Y, Itoyama Y. 1998. Expression of adenovirus-mediated E. coli lacZ gene in skeletal muscles and spinal motor neurons of transgenic mice with a mutant superoxide dismutase gene. Neurosci Lett 246:153-156.
55. Weterman MA, Ajubi N, van Dinter IM, Degen WG, van Muijen GN, Ruitter DJ, Bloemers HP. 1995. nmb, A novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 60:73-81.
56. Wijesekera LC, Leigh PN. 2009. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4:3.
57. Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P. 2010. GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res 20:184-190.
58. Wong M, Martin LJ. 2010. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet 19:2284-2302.
59. Wootz H, Enjin A, Wallen-Mackenzie A, Lindholm D, Kullander K. 2010. Reduced VGLUT2 expression increases motor neuron viability in Sod1(G93A) mice. Neurobiol Dis 37:58-66.
60. Yoo YE, Ko CP. 2012. Dihydrotestosterone ameliorates degeneration in muscle, axons, and motoneurons and improves motor function in amyotrophic lateral sclerosis model mice. PloS One 7:e37258.
61. Yuan QY, Huang J, Chu BC, Li XJ, Li XS, Si LY. 2012. A targeted high-efficiency angiogenesis strategy as therapy for myocardial infarction. Life Sci 90:695-702.
62. Zhang Q, Li Y, Wu Z. 2006. [Research advance of gene therapy for peripheral arterial disease using hepatocyte growth factor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20:1147-1150.